*Eze, I. F 0009-0007-7286-9273., Adeoye-Isijola, M. O 0000-0002-3186-5432., Adefisoye, M. A 0000-0002-4957-4609., and Olajuyigbe, O. O 0000-0002-7889-0416
Department of Microbiology, School of Science and Technology, Babcock University, Ogun State, Nigeria *Correspondence to: ezeifyfaith@gmail.com
Abstract:
Metallo-β-lactamases are different types of biological enzymes that breakdown a broad spectrum of beta-lactam antibiotics such as carbapenems. Antibiotic resistance exhibited by many Gram-negative bacteria is due to acquisition of genes encoding these enzymes, which underscores their importance in antibiotic resistance and has led to an increase in nosocomial infections caused by multi-drug-resistant pathogens. This review analyzes recent updates on the mechanism of antibiotic resistance and epidemiology of metallo-β- lactamases in nosocomial infections. Carbapenem antibiotics are regarded as effective and reserve antibiotics for the treatment of multidrug-resistant bacteria infections. Currently, there is paucity of inhibitors that prevent the activities of metallo beta-lactamase clinically. Carbapenem resistance in bacteria is a global health issue, associated with increased morbidity and mortality in the healthcare setting. There is a need for continuous research on metallo-β-lactamases inhibitors, rational use of carbapenems and appropriate infection control measures in order to curb the increase in infections. This mini-review is aimed to provide a broader scope on the current trends of antimicrobial resistance in metallo-β-lactamase-associated nosocomial infections. This will lead to a better understanding of the public health implication of the unabated spread of these infections, the need for judicious utilization of the limited therapeutic options, resulting to efficient antimicrobial stewardship.
Keywords: Metallo-β-lactamases, β-lactam, Carbapenem, Nosocomial, Multidrug resistant
Received Jan 28, 2025; Revised Apr 21, 2025; Accepted Apr 22, 2025
Download this Article in PDF format below